Display options
Cite
Imam H, Chowdhury A, Mahbub NU, et al. Oxidizability assay of unfractionated plasma of patients' with different plasma profile: a methodological study. J Diabetes Metab Disord. 2014;13:54doi: 10.1186/2251-6581-13-54.
Imam, H., Chowdhury, A., Mahbub, N. U., Hossain, A., Karim, M. F., Uddin, M. B., & Sarker, M. M. (2014). Oxidizability assay of unfractionated plasma of patients' with different plasma profile: a methodological study. Journal of diabetes and metabolic disorders, 1354. https://doi.org/10.1186/2251-6581-13-54
Imam, Hasan, et al. "Oxidizability assay of unfractionated plasma of patients' with different plasma profile: a methodological study." Journal of diabetes and metabolic disorders vol. 13 (2014): 54. doi: https://doi.org/10.1186/2251-6581-13-54
Imam H, Chowdhury A, Mahbub NU, Hossain A, Karim MF, Uddin MB, Sarker MM. Oxidizability assay of unfractionated plasma of patients' with different plasma profile: a methodological study. J Diabetes Metab Disord. 2014 May 01;13:54. doi: 10.1186/2251-6581-13-54. eCollection 2014. PMID: 24918093; PMCID: PMC4031925.
Copy Download .nbib Format: NLM
Share it on

J Diabetes Metab Disord. 2014 May 01;13:54. doi: 10.1186/2251-6581-13-54. eCollection 2014.

Oxidizability assay of unfractionated plasma of patients' with different plasma profile: a methodological study.

Journal of diabetes and metabolic disorders

Hasan Imam, Arfia Chowdhury, Nasir Uddin Mahbub, Amir Hossain, Mohammed Faisal Bin Karim, Mohammad Burhan Uddin, Md Moklesur Rahman Sarker

Affiliations

  1. Department of Pharmacy, Primeasia University, 9 Banani C/A, Dhaka 1213, Bangladesh.
  2. Exim Bank Hospital, 840 Rokeya Soroni, Mirpur, Dhaka 1216, Bangladesh.
  3. Clinical Investigation Centre, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia.

PMID: 24918093 PMCID: PMC4031925 DOI: 10.1186/2251-6581-13-54

Abstract

BACKGROUND: Present study describe the in vitro model of plasma oxidation of patients with different lipid profile, that can be correlated to their invivo plasma oxidizability in order to find the arterial diseases prone patient groups.

METHOD: The method applied here to measure the invitro plasma oxidizability, accounts a convenient way that can be well suited in any clinical laboratory settings. Un-fractionated plasma was exposed to CuSO4 (5.0 mmol/L), a pro-oxidant, and low frequency ultrasonic wave to induce oxidation, and finally oxidizability was calculated by TBARS and Conjugated Diene methods.

RESULT: In our study, plasma LDL greater than 150 mg/dL possess 1.75 times more risk to undergo oxidation (CI, 0.7774 to 3.94; p = 0.071) than the low LDL plasma, percent of oxidation increased from 38.3% to 67.1% for the LDL level upto 150 mg/dL and high. Lag phase, which is considered as the plasma antioxidative protection, was also influenced by the higher LDL concentration. The mean lag time was 65.27 ± 20.02 (p = 0.02 compared to healthy), where as for 94.71 ± 35.11 min for the normolipidemic subject. The plasma oxidizability was also changed drastically for total cholesterol level, oxidative susceptibility shown 35% and 55.02% for 200 mg/dL and high respectively, however it didn't appear as risk factor. Patient samples were also stratified according to their age, gender, and blood glucose level. Older persons (≥40 years) were 1.096 times (95% CL, 0.5607 to 2.141, p = 0.396) than younger (≤39 years age), males are 1.071 (95% CI, 0.5072- 2.264) times than the females, and diabetic patients are 1.091 (CI, 0.6153 to 1.934, p = 0.391) times in more risk than the non-diabetic counterpart.

CONCLUSION: This method addressing its easy applicability in biomedical research. And by this we were able to show that patients with high LDL (≥150 mg/dL) are in alarming condition besides diabetic and elderly (≥40 years age) males are considered to be susceptible and more prone to develop vascular diseases.

Keywords: Conjugated diene; Plasma oxidation; TBARS; Type II Diabetes

References

  1. Ann Intern Med. 1991 Nov 1;115(9):687-93 - PubMed
  2. BMC Clin Pathol. 2001;1(1):1 - PubMed
  3. Nature. 1991 Sep 19;353(6341):265-7 - PubMed
  4. Arterioscler Thromb Vasc Biol. 1995 Dec;15(12):2157-64 - PubMed
  5. N Engl J Med. 1993 Feb 4;328(5):313-8 - PubMed
  6. Clin Chem. 2005 Nov;51(11):2138-44 - PubMed
  7. Nephrol Dial Transplant. 2001 Aug;16(8):1598-606 - PubMed
  8. Circulation. 1999 Oct 26;100(17):1816-22 - PubMed
  9. JAMA. 1984 Jan 20;251(3):351-64 - PubMed
  10. Circulation. 1998 May 12;97(18):1837-47 - PubMed
  11. JAMA. 1986 Nov 28;256(20):2823-8 - PubMed
  12. Clin Chem. 1992 Oct;38(10):2066-72 - PubMed
  13. J Lipid Res. 2000 Sep;41(9):1495-508 - PubMed
  14. Arterioscler Thromb Vasc Biol. 1998 Aug;18(8):1242-7 - PubMed
  15. JAMA. 1987 Apr 24;257(16):2176-80 - PubMed
  16. Prev Med. 1984 Mar;13(2):141-54 - PubMed
  17. BMJ. 1994 Feb 5;308(6925):367-72 - PubMed
  18. Clin Chem. 1972 Jun;18(6):499-502 - PubMed
  19. J Biol Chem. 1997 Aug 22;272(34):20963-6 - PubMed
  20. N Engl J Med. 1990 Jun 14;322(24):1700-7 - PubMed
  21. N Engl J Med. 1990 Oct 18;323(16):1112-9 - PubMed
  22. Circulation. 1992 Mar;85(3):1083-96 - PubMed
  23. Methods Enzymol. 1999;299:35-49 - PubMed
  24. Atherosclerosis. 2005 Apr;179(2):269-75 - PubMed
  25. Lab Invest. 1968 May;18(5):465-7 - PubMed
  26. JAMA. 1984 Jan 20;251(3):365-74 - PubMed
  27. Proc Natl Acad Sci U S A. 1994 Sep 27;91(20):9607-11 - PubMed
  28. J Clin Invest. 1995 Dec;96(6):2758-67 - PubMed
  29. Eur Heart J. 1990 May;11(5):462-71 - PubMed

Publication Types